Dimorphic Fat Inflammation Explains Why Seven Longevity Drugs Fail in Females

News
#1

IL11FatFemaleLongevity-2
IL11FatFemaleLongevity-22752×1536 360 KB

Researchers analyzed tissue from 22-month-old mice to determine why seven prominent anti-aging drugs extend lifespan exclusively in males. The study measured levels of the pro-inflammatory cytokine interleukin-11 across liver, muscle, and adipose tissues. While the drugs successfully lowered interleukin-11 in subcutaneous fat for both sexes, they triggered divergent responses in visceral fat. In males, the interventions suppressed visceral interleukin-11, but in females, five of the seven drugs paradoxically increased it. This dimorphic inflammatory response in abdominal fat suggests a compelling mechanism for the male-exclusive lifespan benefits observed in previous pharmacological trials.

The pharmacological extension of mammalian lifespan faces a persistent and poorly understood hurdle involving sexual dimorphism. The Interventions Testing Program has identified multiple compounds that extend lifespan in male mice while failing to benefit females. This phenomenon limits the clinical translation of these longevity therapeutics.

A specific protein called interleukin-11 acts as a primary driver of age-related inflammation and fibrosis. Earlier research established that blocking interleukin-11 signaling directly extends mammalian lifespan. Building on this foundation, investigators hypothesized that male-specific longevity compounds might operate by suppressing this inflammatory cytokine.

The research team tested tissue from aged mice treated with seven known male-specific longevity drugs. These drugs included canagliflozin, epicatechin, mitoglitazone, halofuginone, astaxanthin, meclizine, and 16-alpha-hydroxyestradiol. The investigators measured interleukin-11 protein levels across liver, skeletal muscle, subcutaneous fat, and visceral perigonadal fat.

The results revealed absolute tissue specificity. None of the seven drugs altered interleukin-11 expression in liver or skeletal muscle. In subcutaneous inguinal fat, the treatments universally reduced the inflammatory cytokine in both male and female subjects.

The critical discovery occurred in visceral perigonadal fat. Six of the seven drugs induced severe sex-specific divergence. Male mice experienced a significant reduction in visceral interleukin-11. Conversely, female mice experienced a paradoxical elevation of the cytokine.

Visceral adipose tissue acts as a central regulatory node for systemic metabolic health. The data indicates that while these pharmaceutical interventions successfully mitigate subcutaneous fat inflammation, they trigger a compensatory inflammatory cascade in female visceral fat. This localized tissue inflammation likely counteracts any systemic benefits the drugs might otherwise provide to females, fully negating potential lifespan extension.

Actionable Insights

Biohackers and clinicians must treat male-specific longevity compounds with caution regarding female longevity protocols. The magnitude of the dimorphic response can be substantial. In male subjects, drugs like mitoglitazone and 16-alpha-hydroxyestradiol reduced visceral interleukin-11 by 50 to 80 percent, demonstrating a massive anti-inflammatory effect size.

For female subjects, the exact same interventions increased visceral interleukin-11 by 20 to 100 percent. Halofuginone doubled the inflammatory marker in female visceral fat. This represents a significant pro-inflammatory insult.

Females utilizing compounds like astaxanthin, epicatechin, or canagliflozin for generalized anti-aging purposes may inadvertently accelerate visceral adipocyte inflammation.

Context/Source

1 Like
#2

Well, so what? All that IL-11 massive inflammation lowering didn’t appear to extend male lifespans either. So are we sure it’s all down to disparate IL-11 response?

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice

https://pubmed.ncbi.nlm.nih.gov/41843349/

“Despite prior evidence suggesting lifespan benefits of these proposed interventions in other models or under different conditions, none of the tested compounds significantly increased lifespan in male or female mice. Notably, astaxanthin, mitoglitazone, and meclizine—previously associated with lifespan extension in the ITP—showed no benefit when administered at different doses or starting at later ages. In females, astaxanthin, late-start mitoglitazone, and pioglitazone were associated with significantly reduced lifespan when pooling the data from all three sites.”

OK, so if the dose or age prevented benefits from appearing for males this time around, there’s always the possibility that the doses in all trials so far have been wrong for the females - maybe females require a different dose from males? Logically you can’t exclude that possibility if you posit that it is the dose that’s responsible for the presence or absence of benefits… so find the dose that works for females/maybe/.

Furthermore, did the different doses of mitoglitazone for males give a different IL-11 response in each case which would account for benefits at one dose and no benefits at another dose? I call BS on the IL-11 being responsible for life extending effects of mitoglitazone unless you can show me that in this trial where there was no benefit to males the different dose resulted in no lowering of IL-11 inflammation… which I doubt.

I have a feeling that this fat/IL-11 differential effect for males and females is not the explanation for this dichotomy, nor has anything to do with life extension either way.

#3

Sure it did:

#4

This is a misunderstanding. You cite the earlier ITP result where mitoglitazone (among others) indeed had a 9% life extension in males but not females.

But when I said “it didn’t appear to extend lifespan” I was referring to the later ITP trial where neither the male nor female mice experienced life extension effects from mitoglitazone (and other compounds which did in the previous ITP trial). And I provided a link and quotation to the study on which I based my statement. It’s a different later ITP study on older mice and lower dosage compared to the first study you linked to (which did show extension in males).

My simple point was: if lifespan extension happens in males on mitoglitazone due to it affecting IL-11 differently from females why did mitoglitazone no longer work in males in the second trial?

Was it because a lower dose in older mice no longer affects IL-11? Please show me that this is what happened to IL-11 in that second trial! Because unless you show me that, my suspicion is that mitoglitazone works exactly the same on IL-11 in both trials, and you don’t get extension the second time around because the extension has nothing to do with IL-11… if IL-11 is key, then it should have worked both times - clearly it is not the mechanism.

So I ask again: were the IL-11 levels measured in the second trial and showed no effect by mitoglitazone because of dose and age of administration.

I am deliberately bringing attention to the disparity between the results of these two trials, as I think that can undermine the IL-11 “causation” claim.